S 1041 · introduced · significant
Affordable Prescriptions for Patients Act
- healthcare
What this bill does
- The bill limits how many patents a biologic drug maker can use in lawsuits against biosimilar competitors.
- Biosimilar manufacturers seeking FDA approval and the reference biologic drug companies are directly affected.
- The limits apply to patents filed more than four years after the original drug's market approval, with court discretion to increase limits if warranted.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would limiting the number of patents biologic companies can assert affect the speed and cost of bringing biosimilar drugs to market?
- 02
What evidence exists that current patent litigation practices by biologic makers delay biosimilar competition, and is a four-year threshold the right timeframe?
- 03
Could restricting patent enforcement discourage investment in novel biologic drug development, or would savings from biosimilar competition offset that concern?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-TX
John Cornyn
Citizen cosponsors
0
In Congress
3/ 100
Senators cosponsoring
Introduced 2025-04-10
Joining the bill
Legislative timeline
2025-04-10 · senate · Calendars
Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.
2025-04-10 · senate · Committee
Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
2025-04-10 · Committee
Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
2025-04-03 · senate · Committee
Committee on the Judiciary. Ordered to be reported with amendments favorably.
2025-03-13 · senate · IntroReferral
Read twice and referred to the Committee on the Judiciary.
2025-03-13 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.